Pimecrolimus (Elidel) Indications and Dosage
Pimecrolimus Indications and Dosage
For short-term and intermittent long-term treatment of mild to moderate atopic dermatitis (eczema) in non-immunocompromised patients who are unresponsive or intolerant of other therapies or as an alternative to conventional therapies in at-risk patients:
NOTE: Topical pimecrolimus is a second line agent to treat atopic dermatitis in patients unresponsive to or intolerant of other first line agents; long-term safety has not been established.
NOTE: If no improvement occurs after 6 weeks of treatment or if exacerbation of atopic dermatitis occurs, treatment should be stopped and other therapeutic options considered.
Topical dosage:
Adults, adolescents, and children > 2 years: Apply a thin layer to the affected skin area(s) twice daily. Rub in gently and completely. Use for as long as symptoms persist; discontinue if resolution of disease occurs. If symptoms persist beyond 6 weeks, the patient should be re-evaluated.
Patients with hepatic impairment:
No dosage adjustment is necessary.
Patients with renal impairment:
No dosage adjustment is necessary.
[ Last revised: 3/7/2005 6:13:00 PM ]
Related entries
Syndicate
|
